Pharmacogenomics of Type I interferon therapy: A survey of response-modifying genes

Catherine King, Pablo Villoslada, Koen Vandenbroeck

Research output: Contribution to journalShort survey

25 Citations (Scopus)

Abstract

Interferon-β (IFN-β) is routinely prescribed as an immunomodulatory treatment for multiple sclerosis (MS), but is associated with variable clinical efficacy. Ideally an early predictor of response status would allow more rational provision of this therapy. Both pharmacogenomic and expression analysis have highlighted IFN-β regulated genes which may influence treatment efficacy. In this review we have summarized and discussed the main genes identified by these studies in MS patients, and supplemented this with data from similar studies of Type I IFN treatment in hepatitis.

LanguageEnglish
Pages211-222
Number of pages12
JournalCytokine and Growth Factor Reviews
Volume18
Issue number3-4
DOIs
Publication statusPublished - 1 Jun 2007

Keywords

  • Gene expression
  • Hepatitis
  • Interferon
  • Multiple sclerosis
  • Pharmacogenomics
  • Polymorphism

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Immunology and Allergy
  • Immunology
  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

King, Catherine ; Villoslada, Pablo ; Vandenbroeck, Koen. / Pharmacogenomics of Type I interferon therapy : A survey of response-modifying genes. In: Cytokine and Growth Factor Reviews. 2007 ; Vol. 18, No. 3-4. pp. 211-222.
@article{22ddca86498b449ea7c9899368aaa512,
title = "Pharmacogenomics of Type I interferon therapy: A survey of response-modifying genes",
abstract = "Interferon-β (IFN-β) is routinely prescribed as an immunomodulatory treatment for multiple sclerosis (MS), but is associated with variable clinical efficacy. Ideally an early predictor of response status would allow more rational provision of this therapy. Both pharmacogenomic and expression analysis have highlighted IFN-β regulated genes which may influence treatment efficacy. In this review we have summarized and discussed the main genes identified by these studies in MS patients, and supplemented this with data from similar studies of Type I IFN treatment in hepatitis.",
keywords = "Gene expression, Hepatitis, Interferon, Multiple sclerosis, Pharmacogenomics, Polymorphism",
author = "Catherine King and Pablo Villoslada and Koen Vandenbroeck",
year = "2007",
month = "6",
day = "1",
doi = "10.1016/j.cytogfr.2007.04.012",
language = "English",
volume = "18",
pages = "211--222",
journal = "Cytokine and Growth Factor Reviews",
issn = "1359-6101",
publisher = "Elsevier BV",
number = "3-4",

}

Pharmacogenomics of Type I interferon therapy : A survey of response-modifying genes. / King, Catherine; Villoslada, Pablo; Vandenbroeck, Koen.

In: Cytokine and Growth Factor Reviews, Vol. 18, No. 3-4, 01.06.2007, p. 211-222.

Research output: Contribution to journalShort survey

TY - JOUR

T1 - Pharmacogenomics of Type I interferon therapy

T2 - Cytokine and Growth Factor Reviews

AU - King, Catherine

AU - Villoslada, Pablo

AU - Vandenbroeck, Koen

PY - 2007/6/1

Y1 - 2007/6/1

N2 - Interferon-β (IFN-β) is routinely prescribed as an immunomodulatory treatment for multiple sclerosis (MS), but is associated with variable clinical efficacy. Ideally an early predictor of response status would allow more rational provision of this therapy. Both pharmacogenomic and expression analysis have highlighted IFN-β regulated genes which may influence treatment efficacy. In this review we have summarized and discussed the main genes identified by these studies in MS patients, and supplemented this with data from similar studies of Type I IFN treatment in hepatitis.

AB - Interferon-β (IFN-β) is routinely prescribed as an immunomodulatory treatment for multiple sclerosis (MS), but is associated with variable clinical efficacy. Ideally an early predictor of response status would allow more rational provision of this therapy. Both pharmacogenomic and expression analysis have highlighted IFN-β regulated genes which may influence treatment efficacy. In this review we have summarized and discussed the main genes identified by these studies in MS patients, and supplemented this with data from similar studies of Type I IFN treatment in hepatitis.

KW - Gene expression

KW - Hepatitis

KW - Interferon

KW - Multiple sclerosis

KW - Pharmacogenomics

KW - Polymorphism

UR - http://www.scopus.com/inward/record.url?scp=34250205988&partnerID=8YFLogxK

U2 - 10.1016/j.cytogfr.2007.04.012

DO - 10.1016/j.cytogfr.2007.04.012

M3 - Short survey

VL - 18

SP - 211

EP - 222

JO - Cytokine and Growth Factor Reviews

JF - Cytokine and Growth Factor Reviews

SN - 1359-6101

IS - 3-4

ER -